KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Intangibles (2021 - 2025)

Historic Intangibles for Regeneron Pharmaceuticals (REGN) over the last 5 years, with Q4 2025 value amounting to $1.3 billion.

  • Regeneron Pharmaceuticals' Intangibles rose 947.24% to $1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $1.3 billion, marking a year-over-year increase of 947.24%. This contributed to the annual value of $1.3 billion for FY2025, which is 947.24% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Intangibles stood at $1.3 billion for Q4 2025, which was up 947.24% from $1.4 billion recorded in Q3 2025.
  • Regeneron Pharmaceuticals' 5-year Intangibles high stood at $1.4 billion for Q3 2025, and its period low was $6.7 million during Q4 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Intangibles had a median value of $1.1 billion in 2024 and averaged $1.0 billion.
  • In the last 5 years, Regeneron Pharmaceuticals' Intangibles skyrocketed by 1356417.91% in 2022 and then skyrocketed by 947.24% in 2025.
  • Quarter analysis of 5 years shows Regeneron Pharmaceuticals' Intangibles stood at $6.7 million in 2021, then surged by 13564.18% to $915.5 million in 2022, then grew by 13.45% to $1.0 billion in 2023, then rose by 10.59% to $1.1 billion in 2024, then increased by 9.47% to $1.3 billion in 2025.
  • Its last three reported values are $1.3 billion in Q4 2025, $1.4 billion for Q3 2025, and $1.4 billion during Q2 2025.